References
- Gupta N, Bagga V, Parmar BJ, Kar K, Mukherjee A, Mehta S, Moharana AK. Efficacy and tolerability assessment of cefprozil in children with acute otitis media. Indian J Pediatr 2004; 71: 319–24
- Bhargava S, Lodha R, Kabra SK. Cefprozil: a review. Indian J Pediatr 2003; 70: 395–400
- Cazzola M. Novel oral cephalosporins. Expert Opin Investig Drugs 2000; 9: 237–46
- Liu YC, Huang WK, Chen DL. Antibacterial activity of cefprozil in vitro. Chemotherapy 1995; 41: 427–32
- Stutman HR. Cefprozil. Pediatr Ann 1993;22:167–8, 171–6.
- Gainer RB 2nd. Cefprozil, a new cephalosporin: its use in various clinical trials. South Med J 1995;88:338–46.
- Gupta N, Mukherjee A, Moharana AK. Paediatric tonsillopharyngitis: an evaluation of cefprozil in Indian patients. Indian J Pediatr 2004; 71: 601–5
- Wilber RB, Doyle CA, Durham SJ, Conetta BJ, DeGraw SS, Leigh A. Safety profile of cefprozil. Clin Infect Dis 1992; 14(Suppl 2)S264–71
- Baciewicz AM, Chandra R. Cefprozil-induced rash in infectious mononucleosis. Ann Pharmacother 2005; 39: 974–5
- Lowery N, Kearns GL, Young RA, Wheeler JG. Serum sickness-like reactions associated with cefprozil therapy. J Pediatr 1994; 125: 325–8
- Shyu WC, Pittman KA, Wilber RB, Matzke GR, Barbhaiya RH. Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment. J Clin Pharmacol 1991; 31: 362–71
- Shyu WC, Wilber RB, Pittman KA, Garg DC, Barbhaiya RH. Pharmacokinetics of cefprozil in healthy subjects and patients with hepatic impairment. J Clin Pharmacol 1991; 31: 372–6
- Lee WM. Drug-induced hepatotoxicity. N Engl J Med 1995; 333: 1118–27
- Marino G, Lewis JH. Drug-induced liver disease. Curr Opin Gastroenterol 2001; 17: 232–41
- Benichou C. Criteria of drug-induced liver disorders. Report of an International Consensus Meeting. J Hepatol 1990; 11: 272–6